Intersect ENT

Acquired

PROPEL™ Sinus Implant

Public · Menlo Park, United States · Founded 2003 · $60.0M raised

Employees
201–500
Founded
2003
Business Model
B2B
Total Funding
$60.0M
Last Round
$30.0M Series DFeb 2013
Rounds
2
Type
Public
Acquired by
MedtronicAug 2021 · $936.0M

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Intersect ENT was a Menlo Park, California-based medical device company that developed and commercialized drug-eluting sinus implants, including the PROPEL and SINUVA products, designed to improve outcomes for ENT surgical patients. Founded in 2003, it was publicly traded before being acquired by Medtronic in May 2022 for approximately $1.1 billion.

Summary

Intersect ENT is a Biotech company based in Menlo Park, United States, founded in 2003. It has raised $60.0M in total across 2 rounds, most recently a $30.0M Series D round in Feb 2013. Investors include Medtronic, Kleiner Perkins and Norwest Venture Partners.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

AcquisitionAug 2021

Sign up to see all 4 events

Funding: Series C through Series D. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Intersect ENT on Indexed.vc
<a href="https://indexed.vc/companies/intersect-ent"><img src="https://indexed.vc/api/badge/company/intersect-ent" alt="Intersect ENT on Indexed.vc" width="260" height="76" /></a>